Boundless Bio (BOLD) vs Xilio Therapeutics (XLO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Boundless Bio (BOLD) has outperformed Xilio Therapeutics (XLO) over the past year, gaining 114.6% versus a loss of 21.7%. Boundless Bio is the larger company by market cap ($60.1 million vs $59.3 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BOLD | XLO |
|---|---|---|
| Share price | $2.64 | $9.01 |
| Market cap | $60.05M | $59.29M |
| 1-day change | +2.72% | +0.11% |
| YTD return | +120.00% | +0.56% |
| 1-year return | +114.63% | -21.71% |
| EPS (TTM) | $-2.91 | $-0.60 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $3.16 | $12.59 |
| 52-week low | $0.961 | $6.47 |
| Distance from 52-week high | -16.56% | -28.41% |
| Average volume | 180.13K | 20.06K |
| Shares outstanding | 22.75M | 6.58M |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- BOLD has outperformed XLO by 136.3 percentage points over the past year.
BOLD vs XLO FAQ
Which is bigger, Boundless Bio or Xilio Therapeutics?
Boundless Bio (BOLD) is larger, with a market capitalization of $60.05M compared with $59.29M for Xilio Therapeutics (XLO).
Which stock has performed better over the past year, BOLD or XLO?
BOLD returned +114.63% over the past 12 months, compared with -21.71% for XLO (price return, excluding dividends). Past performance does not predict future results.
Are Boundless Bio and Xilio Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.